Completed A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors NCT03760081 Conditions Incurable Platinum Refractory Germ Cell Tumors, Neoplasms, Tumors Locations Indiana University Simon Cancer Center — Indianapolis, Indiana, United States Memorial Sloan-Kettering Cancer Center — New York, United States Abramson Cancer Center University of Pennsylvania — Philadelphia, Pennsylvania, United States View Trial Details
